Clinical trials: Hematopoietic
Leukemia, High Risk Acute Lymphoblastic Leukemia
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections.
- Conditions
- Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia
- Trial name
- NCT06839456
- Testing
- Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Philadelphia
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors
This clinical trial develops and test a yoga intervention in improving cancer-related stress in cancer survivors. The online hatha yoga intervention of breathing and movement incorporates both restorative poses, breathing…
- Trial name
- NCT04754529
- Testing
- Quality-of-Life Assessment, Survey Administration, Yoga
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Roswell Park Cancer Institute
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery
This clinical trial tests how well guided meditation, compared to silence, works to reduce pre-operative anxiety in patients undergoing cancer-directed surgery.
- Trial name
- NCT06949943
- Testing
- Behavioral Intervention, Electronic Health Record Review, Survey Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Patients Who Have Received Allo-HSCT
Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine whether nilotinib is effective in the prophylaxis and treatment of CMV reactivation in allo-HSCT patients.
- Trial name
- NCT01252017
- Testing
- nilotinib
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- National Taiwan University Hospital
Acute Lymphocytic Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side…
- Trial name
- NCT03104491
- Testing
- Inotuzumab Ozogamicin
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Leland Metheny
Hematologic Malignancy, Caregiver
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
The goal of this randomized clinical trial is to evaluate whether a positive psychology intervention (PATH-C) can improve psychological well-being, quality of life, and physical activity in caregivers of patients undergoing…
- Trial name
- PATH-C (NCT06153797)
- Testing
- PATH-C
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Brigham and Women's Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hematopoietic Stem Cell Transplantation
Employment Support After Hematopoietic Stem Cell Transplantation
This is a feasibility study of a Work Support (WorkS) intervention designed to ameliorate employment challenges for people preparing to return to work after allogeneic stem cell transplantation.
- Trial name
- WorkS (NCT06494423)
- Testing
- Work Support (WorkS)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- MGH Institute of Health Professions
Myelofibrosis (MF), HSCT
Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis
The investigators evaluate the efficacy and safety of Gecacitinib in patients with myelofibrosis (MF) before, during, and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- CONTINUUM-MF (NCT07471503)
- Testing
- Gecacitinib (also known as Jaktinib)
- Volunteers
- 39 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
This clinical trial evaluates the safety and effectiveness of adding itacitinib to cyclophosphamide and tacrolimus for the prevention of graft versus host disease (GVHD) in patients undergoing hematopoietic stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05364762
- Testing
- Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Stem Cell Transplantation, Hematopoietic, Mesenchymal Stem Cells
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Mesenchymal Stem Cells, Poor Graft Function, Hematological Diseases
- Trial name
- NCT01763086
- Testing
- Mesenchymal stem cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Circulating Hematopoietic Stem Cells
The Effect of Hyperbaric Oxygen Therapy on Circulating Hematopoietic Stem Cell Population
Hematopoietic stem cells (HSCs), which govern the production of all blood lineages, transition through a series of functional states characterized by expansion during fetal development, functional quiescence in adulthood, and…
- Trial name
- NCT06748586
- Testing
- Hyperbaric Oxygen Therapy
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Immunodeficiency, Hematopoietic Stem Cell Transplantation
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Background: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers.
- Trial name
- NCT05027945
- Testing
- Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Allogeneic Hematopoietic Stem Cell Transplantation
Co-transplantation of MSC in the Setting of Allo-HSCT
Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04247945
- Testing
- Cotransplant with MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Hematological Malignancies
Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone…
- Trial name
- NCT00580450
- Testing
- Thymosin alpha 1
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- University Of Perugia
GVHD - Graft-Versus-Host Disease, HSCT
Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical…
- Conditions
- GVHD - Graft-Versus-Host Disease, HSCT, Haploidentical Stem Cell Transplantation
- Trial name
- REDUCy (NCT07193420)
- Testing
- Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT06013423
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
This phase II trial tests how well ruxolitinib with tacrolimus and methotrexate work to prevent the development of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06128070
- Testing
- Biospecimen Collection, Chest Computed Tomography, Echocardiography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
HSCT
The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT
This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT07450313
- Testing
- Luspatercept
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.